Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

Oncology Drugs Approved For Rheumatoid arthritis by US FDA

IPN, New Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals. Specialized in Oncology and other pharma products. IPN can facilitate patient to import of "Bladder Anti-Cancer Products" for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Get Access to FDA Approved Drugs / Anti-Cancer Medicines
For Rheumatoid arthritis Treatment in India

A chronic inflammatory disorder affecting many joints, including those in the hands and feet. In rheumatoid arthritis, the body's immune system attacks its own tissue, including joints. In severe cases, it attacks internal organs. Rheumatoid arthritis affects joint linings, causing painful swelling. Over long periods of time, the inflammation associated with rheumatoid arthritis can cause bone erosion and joint deformity. While there's no cure for rheumatoid arthritis, physiotherapy and medication can help slow the disease's progression. Most cases can be managed with a class of medications called anti-rheumatic drugs (DMARDS)

The following lists anti-cancer drugs, US FDA and Indian Generic brand approved by the Food and Drug Administration (FDA) for Rheumatoid arthritis treatment. The list includes generic and brand names are in some way related to, or used in the treatment of this condition. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

CIMZIA

CIMZIA (certolizumab pegol) injection, for subcutaneous use. Initial U.S. Approval: 2008
Drug / Medicine Name : certolizumab pegol (Cimzia)
Drug Class : tumor necrosis factor (TNF) blocker
Administration : subcutaneous injection at weeks 0, 2, and 4, then every 2-4 weeks
Company : UCB, Inc.
FDA Approved for RA : 13-May-2009
Indication : moderately to severely active RA, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial, pondyloarthritis, plaque psoriasis

More Details...
HUMIRA

HUMIRA (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002
Drug / Medicine Name : adalimumab (Humira)
Drug Class : tumor necrosis factor (TNF) blocker
Administration : subcutaneous injection every 2 weeks
Company : AbbVie Inc.
FDA Approved for RA : 31-Dec-2002
Indication : moderately to severely active RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis

More Details...
ORENCIA

ORENCIA (abatacept) for injection for intravenous use. injection, for subcutaneous use. Initial U.S. Approval: 2005
Drug / Medicine Name : abatacept (Orencia)
Drug Class : selective T cell costimulation modulator
Administration : intravenous infusion at 0, 2 and 4 weeks, then every 4 weeks subcutaneous injection once weekly
Company : Bristol-Myers Squibb Company
FDA Approved for RA : 23-Dec-2005
Indication : moderately to severely active RA, juvenile idiopathic arthritis, psoriatic arthritis, prophylaxis of acute graft versus host disease (aGVHD)

More Details...
RITUXAN

RITUXAN (rituximab) injection, for intravenous use. Initial U.S. Approval: 1997
Drug / Medicine Name : rituximab (Rituxan)
Drug Class : CD20-directed cytolytic antibody
Administration : intravenous infusion two infusions separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation (not sooner than every 16 weeks)
Company : Genentech, Inc.
FDA Approved for RA : 28-Feb-2006 Indication : moderately-to severely-active RA in combination with methotrexate inadequate response to one or more TNF antagonist therapies, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, pemphigus vulgaris

More Details...
REMICADE

REMICADE (infliximab) Lyophilized Concentrate for Injection, for Intravenous Use. Initial U.S. Approval: 1998
Drug / Medicine Name : infliximab (Remicade)
Drug Class : tumor necrosis factor (TNF) blocker
Administration : intravenous infusion at 0, 2, and 6 weeks, then every 8 weeks
Company : Janssen Biotech, Inc.
FDA Approved for RA : 10-Nov-1999
Indication : moderately to severely active RA, in combination with methotrexate, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis

More Details...
STELARA

STELARA (ustekinumab) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2009
STELARA is a prescription medicine used to treat: adults and children 6 years and older with moderate to severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). TALTZ (ixekizumab) injection, for subcutaneous use. Initial U.S. Approval: 2016

More Details...
TALTZ

TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval: 2016. Taltz is an FDA-approved treatment* backed by over a decade of clinical research, and has been relied on by patients since its approval in 2016. For adults with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and for adults and children with moderate to severe plaque psoriasis.

More Details...
XELJANZ XR

XELJANZ XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012
Drug / Medicine Name : tofacitinib (Xeljanz XR)
Drug Class : Janus kinase (JAK) inhibitor
Administration : oral extended-release tablets once daily
Company : Pfizer Inc.
FDA Approved for RA : 23-Feb-2016
Indication : moderately to severely active RA, inadequate response or intolerance to methotrexate, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis.

More Details...
XELJANZ

XELJANZ (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012
Drug / Medicine Name : tofacitinib (Xeljanz)
Drug Class : Janus kinase (JAK) inhibitor
Administration : oral tablets twice daily
Company : Pfizer Inc.
FDA Approved for RA : 6-Nov-2012
Indication : moderately to severely active RA, inadequate response or intolerance to methotrexate, psoriatic arthritis, ankylosing spondylitis ulcerative colitis, polyarticular course, juvenile idiopathic arthritis

More Details...
Enbrel

Enbrel (etanercept) Solution for Subcutaneous Use Initial U.S. Approval: 1998
Drug / Medicine Name : etanercept (Enbrel)
Drug Class : tumor necrosis factor (TNF) blocker subcutaneous injection
Administration : once weekly
Company : Immunex Corporation
FDA Approved for RA : 2-Nov-1998
Indication : moderately to severely active RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis

More Details...

Your Query Form

Head Office

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi, New Delhi:110016 India.

Mobile / WhatsApp Number:
Mobile: +91-9891296838 / 9811747774
WhatsApp: +91-9891296838 / 9811747774

Contact Details:
Phone: +91-11-26532129 / 26536398
Fax: +91-11-26532129 / 26536398

E Mail:
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Social Media:
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Indian Pharma Network is registered medical pharmacy for Oncology Products in India.Helps you to access FDA approved Rheumatoid arthritis medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery. We have helped more than 6,000 patients. Send your enquiry to find the What is the cost of Rheumatoid arthritis Medicines in China, UAE, Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

If you have a question relating to anti-cancer medicines approved for treatment of Rheumatoid arthritis, a problem which you do not know how to resolve it, or concrete inquiry - we are here for you. We will answer you via email urgent@indianpharmanetwork.co.in as soon as possible. If you prefer to be contacted by phone, please leave your phone number. Or text your message in WhatsApp Number +91 9891296838 / 9811747774.

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa